View article

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues, the deployment of safe and effective vaccines presents a key intervention for mitigating disease severity and spread. Numerous logistical challenges and shortages have emerged alongside the international distribution of approved vaccines. In response, several countries have chosen to delay the second dose in an effort to increase the number of individuals receiving at least one dose. A key question then becomes how the timing of delivery of the second dose will affect future epidemiological and evolutionary outcomes.

We build on an existing immuno-epidemiological framework that assumes that, without vaccination, individual immunity after recovery from primary infection may eventually wane, leading to (a potentially reduced) susceptibility to secondary infections. To explore …